In esophageal cancer, dysregulation of the FBXO4-cyclin D1-RB axis promotes glutamine addiction and highlights a therapeutic weakness for overcoming CDK4/6 inhibitor resistance [52]. This evidence concerns the gene FBXO4 and esophageal cancer.